Biogen Idec Refocusing On U.S. Avonex Sales While Awaiting Tysabri's Fate
This article was originally published in The Pink Sheet Daily
Executive Summary
Multiple sclerosis product is up 10%, driven by European sales, but the U.S. market remains disappointing.
You may also be interested in...
Biogen Idec Gains Phase II MS, Cancer Biologics Through PDL Deal
The agreement gives Biogen rights to Protein Design Labs' daclizumab, volociximab and fontolizumab.
Biogen Idec Gains Phase II MS, Cancer Biologics Through PDL Deal
The agreement gives Biogen rights to Protein Design Labs' daclizumab, volociximab and fontolizumab.
Copaxone Growth Helps Teva Offset Declining Generics Business
Strong sales for the multiple sclerosis therapy eased the impact of $100 mil. decline in U.S. generics revenue.